Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Not Confirmed
Not Confirmed
10-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Industry Trade Show
Not Confirmed
10-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
20 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/minghui-pharmaceutical-announces-first-patient-dosed-in-the-phase--combination-study-of-pd-1xvegf-bispecific-and-trop-2-adc-in-advanced-nsclc-302460254.html
09 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/minghui-pharmaceutical-announces-strategic-partnership-and-licensing-agreement-with-qilu-pharmaceutical-to-develop-b7-h3-adc-in-greater-china-302450962.html
06 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/minghui-pharmaceutical-announces-promising-initial-results-from-phase-i-clinical-trial-of-mhb039a-a-novel-pd-1-x-vegf-bispecific-antibody-in-patients-with-relapsedrefractory-solid-tumors-302297285.html
22 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/minghui-pharmaceutical-inc-announces-positive-topline-results-from-phase-ibii-clinical-trial-of-mhb018a-a-subcutaneous-single-domain-igf-1r-antibody-in-patients-with-active-moderate-to-severe-thyroid-eye-disease-ted-302282769.html
22 Oct 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/minghuis-thyroid-eye-disease-drug-slashes-eye-bulging-midstage-trial
03 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/minghui-pharmaceutical-presents-phase-12-clinical-data-of-mhb088c-b7-h3-adc-as-monotherapy-for-the-treatment-of-patients-with-recurrent-or-metastatic-solid-tumors-at-the-2024-asco-annual-meeting-302161236.html
ABOUT THIS PAGE